Translational Medicine

This book brings together a range of academic, industry and practitioner perspectives on translational medicine (TM). It enhances conceptual and practical understanding of the emergence and progress of the field and its potential impact on basic research, therapeutic development, and institutional infrastructure. In recognition of the various impli

James Mittra is a research fellow and lecturer at the ESRC Innogen Centre and Science, Technology and Innovation Studies subject group at the University of Edinburgh. His research and teaching focuses on interdisciplinary approaches to the complex and dynamic ways in which life sciences are affecting the nature and the process of technological and therapeutic innovation within the pharmaceutical and biotechnology sectors. Dr. Mittra has published widely on issues of the strategic management and governance of the life sciences, as well as on mapping new value systems and business models for novel therapies. Christopher-Paul Milne is director of research at the Tufts Center for the Study of Drug Development. His current research interests include academic-industry collaborations; disease, demographic, and market access factors in the emerging markets; incentive programs for pediatric studies, orphan products, and neglected diseases; and tracking the progress of new regulatory and research initiatives such as regulatory science, comparative effectiveness research, translational medicine, and personalized medicine. Dr. Milne is also research assistant professor at Tufts University Medical School, member of the editorial board of the Food & Drug Law Journal, and an honorary fellow at the University of Edinburgh.

Introduction: Introduction to Translational Medicine. Drivers and Barriers to Translational Medicine: New Light Through an Old Window? The "Translational Turn" in Biomedical Research- A Historical Perspective. Translational Medicine: The Industry Perspective. Drivers and Barriers of Translational Medicine: A Regulatory Perspective. Developing an Evaluation Model for Translational Medicine Research Programs. State of the Art in Science and Technology: Emerging Concepts in Biomarker Discovery: Cancer Immunotherapy and Degenerative Diseases of the Eye as Model Systems. Imaging Biomarkers for Innovative Drug Development: Translation from Bench to Bedside and Back. Translational Bioinformatics: Bridging the Biological and Clinical Divide. Institutional Dynamics of Translational Medicine: Exploiting Translational Medicine Through Public-Private Partnerships: A Case Study of Scotland's Translational Medicine Research Collaboration (TMRC). The Role of the Product Development Partnership as a Translational Mechanism for Delivering Health Solutions in Low-Resource Settings. Conclusions: Is Translational Medicine the Future of Therapy?